{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T19:18:45Z","timestamp":1789154325862,"version":"build-2803163510"},"reference-count":47,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2021,2,26]],"date-time":"2021-02-26T00:00:00Z","timestamp":1614297600000},"content-version":"vor","delay-in-days":56,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008730","name":"Norwegian Cancer Society","doi-asserted-by":"publisher","award":["144402"],"award-info":[{"award-number":["144402"]}],"id":[{"id":"10.13039\/100008730","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>The survival rates in population-based series of glioblastoma (GBM) differ substantially from those reported in clinical trials. This discrepancy may be attributed to that patients recruited to trials tend to be younger with better performance status. However, the proportion and characteristics of the patients in a population considered either eligible or ineligible for trials is unknown. The generalizability of trial results is therefore also uncertain.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Using the Cancer Registry of Norway and the Brain Tumor Database at Oslo University Hospital, we tracked all patients within a well-defined geographical area with newly diagnosed GBM during the years 2012\u20132017. Based on data from these registries and the medical records, the patients were evaluated for trial eligibility according to criteria employed in recent phase III trials for GBM.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>We identified 512 patients. The median survival was 11.7 months. When we selected a potential trial population at the start of concurrent chemoradiotherapy (radiotherapy [RT]\/ temozolomide [TMZ]) by the parameters age (18\u201370 y), passed surgery for a supratentorial GBM, Eastern Cooperative Oncology Group (ECOG) \u22642, normal hematologic, hepatic and renal function, and lack of severe comorbidity, 57% of the patients were excluded. Further filtering the patients who progressed during RT\/TMZ and never completed RT\/TMZ resulted in exclusion of 59% and 63% of the patients, respectively. The survival of patients potentially eligible for trials was significantly higher than of the patients not fulfilling trial eligibility criteria (P &amp;lt; .0001).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Patients considered eligible for phase III clinical trials represent a highly selected minority of patients in a real-world GBM population.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/noajnl\/vdab008","type":"journal-article","created":{"date-parts":[[2021,2,28]],"date-time":"2021-02-28T00:28:13Z","timestamp":1614472093000},"source":"Crossref","is-referenced-by-count":23,"title":["Real-world validity of randomized controlled phase III trials in newly diagnosed glioblastoma: to whom do the results of the trials apply?"],"prefix":"10.1093","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3942-3492","authenticated-orcid":false,"given":"Erlend","family":"Skaga","sequence":"first","affiliation":[{"name":"Vilhelm Magnus Laboratory for Neurosurgical Research, Institute for Surgical Research and Department of Neurosurgery, Oslo University Hospital, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marthe Andrea","family":"Skretteberg","sequence":"additional","affiliation":[{"name":"Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom B\u00f8rge","family":"Johannesen","sequence":"additional","affiliation":[{"name":"Department of Registration, Cancer Registry of Norway, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petter","family":"Brandal","sequence":"additional","affiliation":[{"name":"Department of Oncology, Oslo University Hospital, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Einar O","family":"Vik-Mo","sequence":"additional","affiliation":[{"name":"Vilhelm Magnus Laboratory for Neurosurgical Research, Institute for Surgical Research and Department of Neurosurgery, Oslo University Hospital, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eirik","family":"Helseth","sequence":"additional","affiliation":[{"name":"Vilhelm Magnus Laboratory for Neurosurgical Research, Institute for Surgical Research and Department of Neurosurgery, Oslo University Hospital, Oslo, Norway"},{"name":"Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iver A","family":"Langmoen","sequence":"additional","affiliation":[{"name":"Vilhelm Magnus Laboratory for Neurosurgical Research, Institute for Surgical Research and Department of Neurosurgery, Oslo University Hospital, Oslo, Norway"},{"name":"Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,2,26]]},"reference":[{"issue":"5","key":"2021022723082587000_CIT0001","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1470-2045(09)70025-7","article-title":"Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial","volume":"10","author":"Stupp","year":"2009","journal-title":"Lancet Oncol"},{"issue":"9","key":"2021022723082587000_CIT0002","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1093\/neuonc\/nos153","article-title":"A population-based study on the effect of temozolomide in the treatment of glioblastoma multiforme","volume":"14","author":"R\u00f8nning","year":"2012","journal-title":"Neuro Oncol."},{"issue":"3","key":"2021022723082587000_CIT0003","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1093\/neuonc\/nor218","article-title":"Patterns of care and survival for patients with glioblastoma multiforme diagnosed during 2006","volume":"14","author":"Yabroff","year":"2012","journal-title":"Neuro Oncol"},{"issue":"0","key":"2021022723082587000_CIT0004","first-page":"44015","article-title":"Survival benefit of glioblastoma patients after FDA approval of temozolomide concomitant with radiation and bevacizumab: A population-based study","volume":"5","author":"Zhu","year":"2014","journal-title":"Oncotarget"},{"issue":"3","key":"2021022723082587000_CIT0005","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1093\/neuonc\/noy164","article-title":"Glioblastoma survival is improving despite increasing incidence rates: a nationwide study between 2000 and 2013 in Finland","volume":"21","author":"Korja","year":"2018","journal-title":"Neuro Oncol"},{"issue":"9453","key":"2021022723082587000_CIT0006","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/S0140-6736(04)17670-8","article-title":"External validity of randomised controlled trials: \u201cTo whom do the results of this trial apply?\u201d","volume":"365","author":"Rothwell","year":"2005","journal-title":"The Lancet"},{"issue":"32","key":"2021022723082587000_CIT0007","doi-asserted-by":"crossref","first-page":"4085","DOI":"10.1200\/JCO.2013.49.6968","article-title":"Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial","volume":"31","author":"Gilbert","year":"2013","journal-title":"J Clin Oncol."},{"issue":"10","key":"2021022723082587000_CIT0008","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1016\/S1470-2045(14)70379-1","article-title":"Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial","volume":"15","author":"Stupp","year":"2014","journal-title":"The Lancet Oncology"},{"issue":"8","key":"2021022723082587000_CIT0009","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1308573","article-title":"A randomized trial of bevacizumab for newly diagnosed glioblastoma","volume":"370","author":"Gilbert","year":"2014","journal-title":"New Engl J Med"},{"issue":"8","key":"2021022723082587000_CIT0010","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJMoa1308345","article-title":"Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma","volume":"370","author":"Chinot","year":"2014","journal-title":"N Engl J Med."},{"issue":"4","key":"2021022723082587000_CIT0011","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.ejca.2014.12.019","article-title":"A randomised, open label phase III trial with nimotuzumab, an anti-epidermal growth factor receptor monoclonal antibody in the treatment of newly diagnosed adult glioblastoma","volume":"51","author":"Westphal","year":"2015","journal-title":"Eur J Cancer."},{"issue":"10","key":"2021022723082587000_CIT0012","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1016\/S1470-2045(17)30517-X","article-title":"Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial","volume":"18","author":"Weller","year":"2017","journal-title":"Lancet Oncol."},{"issue":"23","key":"2021022723082587000_CIT0013","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1001\/jama.2017.18718","article-title":"Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma","volume":"318","author":"Stupp","year":"2017","journal-title":"JAMA"},{"issue":"4","key":"2021022723082587000_CIT0014","doi-asserted-by":"crossref","first-page":"7003","DOI":"10.18632\/oncotarget.12273","article-title":"Phase III randomized trial of autologous cytokine-induced killer cell immunotherapy for newly diagnosed glioblastoma in Korea","volume":"8","author":"Kong","year":"2017","journal-title":"Oncotarget."},{"key":"2021022723082587000_CIT0015","doi-asserted-by":"crossref","DOI":"10.1186\/s12967-018-1552-1","article-title":"First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma","author":"Liau","year":"2018:16(142)","journal-title":"J Transl Med"},{"issue":"10172","key":"2021022723082587000_CIT0016","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/S0140-6736(18)31791-4","article-title":"Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG\/NOA-09): a randomised, open-label, phase 3 trial","volume":"393","author":"Herrlinger","year":"2019","journal-title":"Lancet."},{"issue":"3","key":"2021022723082587000_CIT0017","doi-asserted-by":"crossref","first-page":"467","DOI":"10.3171\/jns.2003.99.3.0467","article-title":"Survival following surgery and prognostic factors for recently diagnosed malignant glioma: data from the Glioma Outcomes Project","volume":"99","author":"Laws","year":"2003","journal-title":"J Neurosurg."},{"issue":"3","key":"2021022723082587000_CIT0018","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/j.1600-0404.2010.01350.x","article-title":"Overall survival, prognostic factors, and repeated surgery in a consecutive series of 516 patients with glioblastoma multiforme","volume":"122","author":"Helseth","year":"2010","journal-title":"Acta Neurol Scand."},{"issue":"11","key":"2021022723082587000_CIT0019","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1001\/jamaoncol.2016.1373","article-title":"Association of the extent of resection with survival in glioblastoma: a systematic review and meta-analysis","volume":"2","author":"Brown","year":"2016","journal-title":"JAMA Oncology"},{"issue":"11","key":"2021022723082587000_CIT0020","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1016\/j.jocn.2012.04.005","article-title":"The impact of enrollment in clinical trials on survival of patients with glioblastoma","volume":"19","author":"Shahar","year":"2012","journal-title":"J Clin Neurosci."},{"issue":"7","key":"2021022723082587000_CIT0021","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1016\/j.ejca.2008.10.037","article-title":"Data quality at the Cancer Registry of Norway: an overview of comparability, completeness, validity and timeliness","volume":"45","author":"Larsen","year":"2009","journal-title":"Eur J Cancer."},{"issue":"1","key":"2021022723082587000_CIT0022","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s00401-005-0991-y","article-title":"Epidemiology and etiology of gliomas","volume":"109","author":"Ohgaki","year":"2005","journal-title":"Acta Neuropathol."},{"issue":"7","key":"2021022723082587000_CIT0023","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1093\/neuonc\/noq030","article-title":"Oncological patterns of care and outcome for 952 patients with newly diagnosed glioblastoma in 2004","volume":"12","author":"Bauchet","year":"2010","journal-title":"Neuro Oncol"},{"issue":"14","key":"2021022723082587000_CIT0024","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1002\/cncr.30023","article-title":"Glioblastoma in the Canton of Zurich, Switzerland revisited: 2005 to 2009","volume":"122","author":"Gramatzki","year":"2016","journal-title":"Cancer"},{"issue":"7","key":"2021022723082587000_CIT0025","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1093\/neuonc\/nou087","article-title":"The epidemiology of glioma in adults: a \u201cstate of the science\u201d review","volume":"16","author":"Ostrom","year":"2014","journal-title":"Neuro Oncol"},{"key":"2021022723082587000_CIT0026","doi-asserted-by":"crossref","first-page":"v1","DOI":"10.1093\/neuonc\/noz150","article-title":"CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2012\u20132016","volume":"21","author":"Ostrom","year":"2019","journal-title":"Neuro Oncol"},{"issue":"7","key":"2021022723082587000_CIT0027","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/j.clineuro.2012.01.026","article-title":"Glioblastoma: clinical characteristics, prognostic factors and survival in 492 patients","volume":"114","author":"Stark","year":"2012","journal-title":"Clin Neurol Neurosurg."},{"issue":"6","key":"2021022723082587000_CIT0028","doi-asserted-by":"crossref","first-page":"e237","DOI":"10.1016\/j.wneu.2013.02.010","article-title":"Adult cerebellar glioblastoma: understanding survival and prognostic factors using a population-based database from 1973 to 2009","volume":"80","author":"Adams","year":"2013","journal-title":"World Neurosurg"},{"issue":"1","key":"2021022723082587000_CIT0029","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1093\/neuonc\/noy123","article-title":"Distinct genomic profile and specific targeted drug responses in adult cerebellar glioblastoma","volume":"21","author":"Cho","year":"2019","journal-title":"Neuro Oncol."},{"issue":"4","key":"2021022723082587000_CIT0030","first-page":"446","article-title":"Outcomes of presumed malignant glioma treated without pathological confirmation: a retrospective, single-center analysis","volume":"7","author":"Climans","year":"2020","journal-title":"Neurooncol Pract."},{"issue":"1","key":"2021022723082587000_CIT0031","first-page":"37","article-title":"Patterns and disparities of care in glioblastoma","volume":"6","author":"Dressler","year":"2019","journal-title":"Neurooncol Pract."},{"issue":"5","key":"2021022723082587000_CIT0032","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.wneu.2011.12.008","article-title":"Survival and treatment patterns of glioblastoma in the elderly: a population-based study","volume":"78","author":"Gulati","year":"2012","journal-title":"World Neurosurg."},{"issue":"2","key":"2021022723082587000_CIT0033","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1227\/01.NEU.0000371990.86656.E8","article-title":"Patterns of care and survival in a retrospective analysis of 1059 patients with glioblastoma multiforme treated between 2002 and 2007: a multicenter study by the Central Nervous System Study Group of Airo (Italian Association of Radiation Oncology)","volume":"67","author":"Scoccianti","year":"2010","journal-title":"Neurosurgery"},{"issue":"2","key":"2021022723082587000_CIT0034","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s11060-018-2892-7","article-title":"Treatment and survival of glioblastoma patients in Denmark: The Danish Neuro-Oncology Registry 2009\u20132014","volume":"139","author":"Hansen","year":"2018","journal-title":"J Neuro-Oncol"},{"issue":"1","key":"2021022723082587000_CIT0035","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s11060-018-03065-z","article-title":"Association of patterns of care, prognostic factors, and use of radiotherapy\u2013temozolomide therapy with survival in patients with newly diagnosed glioblastoma: a French national population-based study","volume":"142","author":"Fabbro-Peray","year":"2019","journal-title":"J Neuro-Oncol"},{"issue":"18","key":"2021022723082587000_CIT0036","doi-asserted-by":"crossref","first-page":"3175","DOI":"10.1016\/j.ejca.2010.06.126","article-title":"Interconversion of three measures of performance status: an empirical analysis","volume":"46","author":"Ma","year":"2010","journal-title":"Eur J Cancer."},{"issue":"10","key":"2021022723082587000_CIT0037","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N Engl J Med."},{"key":"2021022723082587000_CIT0038","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1186\/s13063-015-1023-4","article-title":"A literature review on the representativeness of randomized controlled trial samples and implications for the external validity of trial results","volume":"16","author":"Kennedy-Martin","year":"2015","journal-title":"Trials."},{"issue":"4","key":"2021022723082587000_CIT0039","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1002\/ana.410260406","article-title":"Selection bias in clinical trials of anaplastic glioma","volume":"26","author":"Winger","year":"1989","journal-title":"Ann Neurol."},{"issue":"2","key":"2021022723082587000_CIT0040","doi-asserted-by":"crossref","first-page":"179","DOI":"10.3171\/jns.1992.76.2.0179","article-title":"Selection bias, survival, and brachytherapy for glioma","volume":"76","author":"Florell","year":"1992","journal-title":"J Neurosurg."},{"issue":"24","key":"2021022723082587000_CIT0041","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1093\/jnci\/87.24.1884","article-title":"Evaluating glioma therapies: modeling treatments and predicting outcomes","volume":"87","author":"Kirby","year":"1995","journal-title":"J Natl Cancer Inst."},{"issue":"4","key":"2021022723082587000_CIT0042","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1212\/WNL.49.4.912","article-title":"Challenges in the design and conduct of phase III brain tumor therapy trials","volume":"49","author":"Perry","year":"1997","journal-title":"Neurology."},{"issue":"4","key":"2021022723082587000_CIT0043","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1215\/S1152851705000554","article-title":"GNOSIS: guidelines for neuro-oncology: standards for investigational studies-reporting of phase 1 and phase 2 clinical trials","volume":"7","author":"Chang","year":"2005","journal-title":"Neuro Oncol."},{"issue":"8","key":"2021022723082587000_CIT0044","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1093\/neuonc\/noy027","article-title":"The clinical trials landscape for glioblastoma: is it adequate to develop new treatments?","volume":"20","author":"Vanderbeek","year":"2018","journal-title":"Neuro Oncol."},{"issue":"5","key":"2021022723082587000_CIT0045","first-page":"536","article-title":"Barriers to accrual and enrollment in brain tumor trials","volume":"31","author":"Lee","year":"2019","journal-title":"Neuro Oncol"},{"issue":"33","key":"2021022723082587000_CIT0046","doi-asserted-by":"crossref","first-page":"3737","DOI":"10.1200\/JCO.2017.73.7916","article-title":"Broadening eligibility criteria to make clinical trials more representative: american society of clinical oncology and friends of cancer research joint research statement","volume":"35","author":"Kim","year":"2017","journal-title":"J Clin Oncol."},{"issue":"5","key":"2021022723082587000_CIT0047","first-page":"601","article-title":"Optimizing eligibility criteria and clinical trial conduct to enhance clinical trial participation for primary brain tumor patients","volume":"22","author":"Lee","year":"2020","journal-title":"Neuro Oncol"}],"container-title":["Neuro-Oncology Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/noa\/article-pdf\/3\/1\/vdab008\/36400742\/vdab008.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/noa\/article-pdf\/3\/1\/vdab008\/36400742\/vdab008.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,28]],"date-time":"2021-02-28T00:28:38Z","timestamp":1614472118000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/noa\/article\/doi\/10.1093\/noajnl\/vdab008\/6152004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,1]]},"references-count":47,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1,1]]}},"URL":"https:\/\/doi.org\/10.1093\/noajnl\/vdab008","relation":{},"ISSN":["2632-2498"],"issn-type":[{"value":"2632-2498","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,1,1]]},"published":{"date-parts":[[2021,1,1]]},"article-number":"vdab008"}}